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A 27-year-old woman with end-stage renal disease secondary to
type I diabetes received a living-related renal transplant in
December 2000. The kidney function immediately improved and
serum creatinine during the first month was between 106 and
124mmol/l. In September 2001, her serum creatinine increased to
292mmol/l. In November 2001, she underwent a renal biopsy,
which showed no evidence of acute cellular rejection.
One week later, she presented to the emergency room with
confusion and falls. The patient’s husband stated that she had
tremors over the previous 4 months, but they had worsened
over the past week. The patient also reported visual
hallucinations beginning 1 day before admission. Her home
medications were acyclovir, amantadine, aspirin, bupropion,
cyclosporine, fluconazole, insulin, isosorbide dinitrate, me-
toclopramide, metoprolol, mycophenolate mofetil, panto-
prazole, prednisone, sulfamethoxazole/trimethoprim, and
warfarin. Additional symptoms of ataxia, agitation, and
aggressive behavior were also present. On examination, the
patient was alert, oriented, and in no apparent distress, but
extremely tremulous. Her blood pressure was 164/90 mm Hg;
however, the remaining physical exam was unremarkable. On
admission, blood urea nitrogen and serum creatinine were
17.1 and 327 mmol/l (estimated creatinine clearance of
0.33 ml/s), respectively. Laboratory results that were remark-
able were the following: serum sodium 125 mmol/l, chloride
90 mmol/l, glucose 15.9 mmol/l, and hemoglobin 102 g/l.
Cyclosporine level was 195 nmol/l. A computed tomography
scan of the head, magnetic resonance imaging of the brain
(Figure 1), electroencephalogram, and electrocardiogram
were performed.
What is the cause of this patient’s altered mental status?
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Figure 1 | Magnetic resonance imaging of the brain.
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The Diagnosis | Amantadine toxicity
As the patient’s amantadine dosage was increased 5 days before
admission, amantadine toxicity was suspected and the drug was
discontinued. The patient’s computed tomography and electro-
cardiogram were unremarkable. Magnetic resonance imaging of
the brain demonstrated chronic ischemic changes. Electroence-
phalogram did not show diffuse slowing. Both serotonin
syndrome and neuroleptic malignant syndrome were ruled out.
Bupropion, sulfamethoxazole/trimethoprim, acyclovir, and meto-
clopramide were also discontinued. High-dose benzodiazepines
were used to control the patient’s agitation and hallucinations over
the next 7 days. Serial amantadine levels were obtained (Figure 2).
Clinical evidence of amantadine toxicity was resolved on day 5 of
hospitalization. She was restarted on bupropion, sulfamethoxazole/
trimethoprim, and metoclopramide at the same doses without
recurrent symptoms. Methylphenidate was added for the treat-
ment of her depression and cognitive deficit. She was discharged 7
days after admission with an improved serum creatinine of
221mmol/l (estimated creatinine clearance of 0.48 ml/s).
Amantadine serum concentrations of greater than 1000 ng/ml
have been associated with toxicity.1 Amantadine toxicity is
associated with central nervous system findings more
commonly in chronic toxicity and with cardiovascular effects
more commonly in acute toxicity.2 Cardiovascular effects that
have been reported with acute amantadine toxicity are
bradycardia, congestive heart failure, hypotension, torsades
de pointes, and ventricular arrhythmias.2 In addition, coma,
seizures, and death have been reported with acute toxicity.2
Central nervous system effects such as agitation, altered mental
status, ataxia, delirium, hallucinations (auditory and visual),
hypersomnia, impaired concentration, insomnia, nightmares,
psychosis, and tremor have been more evident with chronic
toxicity; however, they can occur with acute toxicity.1–3 Risk
factors for chronic amantadine toxicity are concurrent anti-
cholinergic medications, renal impairment, and advanced
age.1–3
The care of renal transplant recipients requires the use of
many drugs with potential interactions, and renal function in
such patients frequently changes. Because 90% of amantadine is
excreted in the urine, it is important to adjust the dose for renal
function in patients with renal impairment to avoid the
accumulation of amantadine and drug toxicity.3 The reason for
this patient’s acute renal insufficiency was not clear. Her renal
biopsy was normal and her cyclosporine concentrations were
not elevated. The increase in her serum creatinine level began
while she was being treated with intravenous acyclovir, and this
is the presumed etiology of her renal insufficiency. There is no
known nephrotoxicity from amantadine, although it might
aggravate renal insufficiency by causing urinary retention. This
case highlights the importance of adjusting amantadine dose
when renal function changes and monitoring for potential
medication interaction in renal transplant recipients.
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Figure 2 | Amanadine measured and estimated serum levels
vs. day of stay. Measured amantadine level (ng/mL);
Esimated amantadine level (ng/mL)
*Estimated serum amantadine levels were calculated using the
patient’s estimated half-life, which was calculated from the true
measured amantadine levels.
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